Caribou Biosciences announces Q4 and FY2025 financial results

Traders Union
All News
Companies
Caribou Biosciences Q4 FY2025 results

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Market Voices

Companies

Ivan Andriyenko

06.03.2026

Caribou Biosciences announces Q4 and FY2025 financial results — Caribou Biosciences Q4 FY2025 results

Caribou Biosciences has announced its financial results for the fourth quarter and full fiscal year 2025.

The company, which is active in cell therapy and gene editing, revealed the figures via an official release. Investors and analysts are reviewing the report for insights into Caribou Biosciences current financial position and future outlook. More details can be accessed through the company’s official channels.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Dangerous but indispensable: Why the crypto market needs bridges

By Anastasiia Chabaniuk
3 hours ago

Dangerous but indispensable: Why the crypto market needs bridges

Editors' Picks

Markus Levin: DePIN could power the AI agent economy

By Eugene Komchuk
9 hours ago

Markus Levin: DePIN could power the AI agent economy

Editors' Picks

Pokémon cards for $2,500: How collectibles became a new form of gambling

By Pavlo Kot
Yesterday

Pokémon cards for $2,500: How collectibles became a new form of gambling

Editors' Picks

All Editors' Top Picks

Latest Caribou News

Longer-term CB-011 results unveiled by Caribou Biosciences at EHA2026

By Elena Nikulina
14.06.2026

Longer-term CB-011 results unveiled by Caribou Biosciences at EHA2026

Companies

Caribou Biosciences presents new data on allogeneic CAR-T cell programs at EHA

By Olga Shendetskaya
12.06.2026

Caribou Biosciences presents new data on allogeneic CAR-T cell programs at EHA

Companies

CB-011 dose escalation data points to advances in relapsed multiple myeloma, Caribou Biosciences launches study update

By Eugene Komchuk
11.06.2026

CB-011 dose escalation data points to advances in relapsed multiple myeloma, Caribou Biosciences launches study update

Companies

All Caribou News

Anastasiia Chabaniuk
3 hours ago

Dangerous but indispensable: Why the crypto market needs bridges

Eugene Komchuk
9 hours ago

Markus Levin: DePIN could power the AI agent economy

Pavlo Kot
Yesterday

Pokémon cards for $2,500: How collectibles became a new form of gambling

Pavlo Kot
18.07.2026

The privacy paradox: How the crypto mixer market has changed

Oleg Tkachenko
17.07.2026

Is Bitcoin right for you? Five traits shared by many cryptocurrency holders

Jose Antonio Gastelum
1 min ago

James Van Straten: Bitcoin short-term holder cost basis stands at $69k

Dmytro Kharkov
10 min ago

George Noble: One of the best stocks in energy sector currently

Parshwa Turakhiya
11 min ago

Mark Sobel: Virtual panel to discuss U.S. and global bond yields

Ivan Andriyenko
16 min ago

Market forecasts BoE reaction, Dario Perkins notes

Daria Chernytska
21 min ago

Binance celebrates 9 years and aims for financial super app, Richard Teng notes

Weekly Top Bonuses

Capitalcore

up to $2,500
deposit bonus for all clients

Your capital is at risk.

Top News

Olga Shendetskaya
3 hours ago

Houthis threaten Saudi shipping as oil market risks deepen

Houthis threaten Saudi shipping as oil market risks deepen

Parshwa Turakhiya
6 hours ago

Jeff Bezos backs AI startup developing next-generation chip materials

Jeff Bezos backs AI startup developing next-generation chip materials

Olga Shendetskaya
8 hours ago

Brent tops $90 as Hormuz tensions fuel oil market fears

Brent tops $90 as Hormuz tensions fuel oil market fears

Eugene Komchuk
9 hours ago

Markus Levin: DePIN could power the AI agent economy

Markus Levin: DePIN could power the AI agent economy

Andrey Mastykin
9 hours ago

Samsung cuts U.S. jobs as consumer electronics business slows

Samsung cuts U.S. jobs as consumer electronics business slows

Top 5 companies for you

United States

Live News

Anton Kharitonov
Now

Apple holds near record highs as AI strategy keeps long-term outlook constructive

Anton Kharitonov
Now

Microsoft stabilizes as investors await AI earnings catalyst

Anton Kharitonov
Now

Alphabet rebounds as AI chip momentum shifts focus to earnings

Mykhailo Ihnatenko
Now

Snowflake shares approach decisive technical resistance

Mykhailo Ihnatenko
Now

Tesla shares attempt to reclaim $382 ahead of earnings

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.